Home

ERIC I RICHMAN

CIK 1313876 · CHIEF EXECUTIVE OFFICER · last filed 2025-06-25

ERIC I RICHMAN is a CHIEF EXECUTIVE OFFICER who has filed 55 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for GANX, was dated Jun 25, 2025. Across all open-market trades the lifetime net is −$414.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $893.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$893.0K

Companies

4

Total Filings

55

Lifetime Open-Market Net

-$414.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GANX Director 292,458 $1.73 $506.0K $102.8K 9 2025-06-25
NeuBase Therapeutics, Inc. (NBSE) Delisted Director 3,585 $0.38 $1.4K $96.4K 7 2022-09-12
ADMA Director 44,030 $8.79 $387.0K $106.3K 11 2020-03-03
Altimmune, Inc. (PIP) Delisted Director 45,490 — — -$719.7K 24 2016-11-23

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-06-25 GANX Grant (A) — $0 EDGAR
2024-07-01 GANX Buy (P) +17,000 $20.7K EDGAR
2024-06-26 GANX Grant (A) — $0 EDGAR
2023-09-22 GANX Exer (M) +54,900 $0 EDGAR
2022-09-22 GANX Grant (A) — $0 EDGAR
2022-09-12 NeuBase Therapeutics, Inc. (NBSE) Delisted Grant (A) — $0 EDGAR
2022-05-27 GANX Buy (P) +2,482 $6.4K EDGAR
2022-05-23 GANX Buy (P) +13,256 $37.0K EDGAR
2022-04-21 GANX Buy (P) +4,922 $38.7K EDGAR
2022-03-07 NeuBase Therapeutics, Inc. (NBSE) Delisted Buy (P) +3,880 $6.4K EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.